First, BBR promotes the expression of cyclin-dependent kinase inhibitors (CDKIs) p21Cip1 and p27Kip1 by regulating the AKT/Forkhead box O3a (FoxO3a)/S-phase kinase-associated protein 2 (Skp2) axis and further induces HCC cell cycle arrest (Li et al., 2018a). The gene discussed is SKP2; the disease is hepatocellular carcinoma.